Published in Gene Therapy Weekly, January 31st, 2002
The trial will be conducted in Zurich and will include at least nine patients with either advanced cutaneous T cell lymphoma (CTCL) or multilesional B cell lymphoma. CTCL is a non-Hodgkin lymphoma that affects the T cells of the immune system. It is a chronic, highly symptomatic, debilitating malignancy that infiltrates the skin. Tumor stage CTCL is generally considered to be incurable.
The Phase I clinical trial will evaluate the safety, the immune effects and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.